Literature DB >> 20709805

Peroxisome proliferator-activated receptor {delta} regulates inflammation via NF-{kappa}B signaling in polymicrobial sepsis.

Basilia Zingarelli1, Giovanna Piraino, Paul W Hake, Michael O'Connor, Alvin Denenberg, Hongkuan Fan, James A Cook.   

Abstract

The nuclear peroxisome proliferator-activated receptor δ (PPARδ) is an important regulator of lipid metabolism. In contrast to its known effects on energy homeostasis, its biological role on inflammation is not well understood. We investigated the role of PPARδ in the modulation of the nuclear factor-κB (NF-κB)-driven inflammatory response to polymicrobial sepsis in vivo and in macrophages in vitro. We demonstrated that administration of GW0742, a specific PPARδ ligand, provided beneficial effects to rats subjected to cecal ligation and puncture, as shown by reduced systemic release of pro-inflammatory cytokines and neutrophil infiltration in lung, liver, and cecum, when compared with vehicle treatment. Molecular analysis revealed that treatment with GW0742 reduced NF-κB binding to DNA in lung and liver. In parallel experiments, heterozygous PPARδ-deficient mice suffered exaggerated lethality when subjected to cecal ligation and puncture and exhibited severe lung injury and higher levels of circulating tumor necrosis factor-α (TNFα) and keratinocyte-derived chemokine than wild-type mice. Furthermore, in lipopolysaccharide-stimulated J774.A1 macrophages, GW0742 reduced TNFα production by inhibiting NF-κB activation. RNA silencing of PPARδ abrogated the inhibitory effects of GW0742 on TNFα production. Chromatin immunoprecipitation assays revealed that PPARδ displaced the NF-κB p65 subunit from the κB elements of the TNFα promoter, while recruiting the co-repressor BCL6. These data suggest that PPARδ is a crucial anti-inflammatory regulator, providing a basis for novel sepsis therapies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20709805      PMCID: PMC2947279          DOI: 10.2353/ajpath.2010.091010

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   5.770


  42 in total

Review 1.  Innate immune recognition: mechanisms and pathways.

Authors:  R Medzhitov; C Janeway
Journal:  Immunol Rev       Date:  2000-02       Impact factor: 12.988

2.  Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer.

Authors:  Yaacov Barak; Debbie Liao; Weimin He; Estelita S Ong; Michael C Nelson; Jerrold M Olefsky; Richard Boland; Ronald M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-26       Impact factor: 11.205

3.  PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells.

Authors:  Yves Rival; Nathalie Benéteau; Thierry Taillandier; Mylène Pezet; Elisabeth Dupont-Passelaigue; Jean François Patoiseau; Didier Junquéro; Francis C Colpaert; André Delhon
Journal:  Eur J Pharmacol       Date:  2002-01-25       Impact factor: 4.432

Review 4.  Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.

Authors:  Jonathan D Brown; Jorge Plutzky
Journal:  Circulation       Date:  2007-01-30       Impact factor: 29.690

5.  Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta).

Authors:  J M Peters; S S Lee; W Li; J M Ward; O Gavrilova; C Everett; M L Reitman; L D Hudson; F J Gonzalez
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

Review 6.  PPARdelta in humans: genetic and pharmacological evidence for a significant metabolic function.

Authors:  Fredrik Karpe; Ewa E Ehrenborg
Journal:  Curr Opin Lipidol       Date:  2009-08       Impact factor: 4.776

Review 7.  Cytokine modulation in sepsis and septic shock.

Authors:  Sergio Zanotti; Aseem Kumar; Anand Kumar
Journal:  Expert Opin Investig Drugs       Date:  2002-08       Impact factor: 6.206

8.  The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice.

Authors:  Tracey L Graham; Claudette Mookherjee; Keith E Suckling; Colin N A Palmer; Lisa Patel
Journal:  Atherosclerosis       Date:  2005-07       Impact factor: 6.847

9.  PPARdelta modulates lipopolysaccharide-induced TNFalpha inflammation signaling in cultured cardiomyocytes.

Authors:  Guoliang Ding; Lihong Cheng; Qianhong Qin; Sonya Frontin; Qinglin Yang
Journal:  J Mol Cell Cardiol       Date:  2006-05-15       Impact factor: 5.763

10.  PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis.

Authors:  Yasunori Takata; Joey Liu; Fen Yin; Alan R Collins; Christopher J Lyon; Chih-Hao Lee; Annette R Atkins; Michael Downes; Grant D Barish; Ronald M Evans; Willa A Hsueh; Rajendra K Tangirala
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-12       Impact factor: 12.779

View more
  40 in total

Review 1.  A historical perspective on sepsis.

Authors:  Peter A Ward; Markus Bosmann
Journal:  Am J Pathol       Date:  2012-05-26       Impact factor: 4.307

2.  Pioglitazone reduces inflammation through inhibition of NF-κB in polymicrobial sepsis.

Authors:  Jennifer Kaplan; Marchele Nowell; Ranjit Chima; Basilia Zingarelli
Journal:  Innate Immun       Date:  2013-09-12       Impact factor: 2.680

3.  Antler extracts stimulate chondrocyte proliferation and possess potent anti-oxidative, anti-inflammatory, and immune-modulatory properties.

Authors:  Baojin Yao; Mei Zhang; Xiangyang Leng; Meixin Liu; Yuxin Liu; Yaozhong Hu; Daqing Zhao; Yu Zhao
Journal:  In Vitro Cell Dev Biol Anim       Date:  2018-05-30       Impact factor: 2.416

4.  Hepatic STAT3 inhibition amplifies the inflammatory response in obese mice during sepsis.

Authors:  Lauren Williamson; Itay Ayalon; Hui Shen; Jennifer Kaplan
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-12-21       Impact factor: 4.310

5.  High fat diet-induced obesity increases myocardial injury and alters cardiac STAT3 signaling in mice after polymicrobial sepsis.

Authors:  Theodore DeMartini; Marchele Nowell; Jeanne James; Lauren Williamson; Patrick Lahni; Hui Shen; Jennifer M Kaplan
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-06-15       Impact factor: 5.187

Review 6.  Early Diagnosis of Sepsis: Is an Integrated Omics Approach the Way Forward?

Authors:  Raymond J Langley; Hector R Wong
Journal:  Mol Diagn Ther       Date:  2017-10       Impact factor: 4.074

Review 7.  Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast, and lung carcinogenesis.

Authors:  Jeffrey M Peters; Jennifer E Foreman; Frank J Gonzalez
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

8.  The chromatin remodeler SRCAP promotes self-renewal of intestinal stem cells.

Authors:  Buqing Ye; Liuliu Yang; Guomin Qian; Benyu Liu; Xiaoxiao Zhu; Pingping Zhu; Jing Ma; Wei Xie; Huimu Li; Tianku Lu; Yanying Wang; Shuo Wang; Ying Du; Zhimin Wang; Jing Jiang; Jinsong Li; Dongdong Fan; Shu Meng; Jiayi Wu; Yong Tian; Zusen Fan
Journal:  EMBO J       Date:  2020-05-25       Impact factor: 11.598

9.  Intestine-Derived Matrix Metalloproteinase-8 Is a Critical Mediator of Polymicrobial Peritonitis.

Authors:  Sarah J Atkinson; Meghan Nolan; Lindsey Klingbeil; Kelli Harmon; Patrick Lahni; Basilia Zingarelli; Hector R Wong
Journal:  Crit Care Med       Date:  2016-04       Impact factor: 7.598

10.  Integrative "omic" analysis of experimental bacteremia identifies a metabolic signature that distinguishes human sepsis from systemic inflammatory response syndromes.

Authors:  Raymond J Langley; Jennifer L Tipper; Shannon Bruse; Rebecca M Baron; Ephraim L Tsalik; James Huntley; Angela J Rogers; Richard J Jaramillo; Denise O'Donnell; William M Mega; Mignon Keaton; Elizabeth Kensicki; Lee Gazourian; Laura E Fredenburgh; Anthony F Massaro; Ronny M Otero; Vance G Fowler; Emanuel P Rivers; Chris W Woods; Stephen F Kingsmore; Mohan L Sopori; Mark A Perrella; Augustine M K Choi; Kevin S Harrod
Journal:  Am J Respir Crit Care Med       Date:  2014-08-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.